- 11-7029-42 - Invitrogen Antibodies IL2 antibody

Submitted references Dynamics of spike-and nucleocapsid specific immunity during long-term follow-up and vaccination of SARS-CoV-2 convalescents.

Koerber N, Priller A, Yazici S, Bauer T, Cheng CC, Mijočević H, Wintersteller H, Jeske S, Vogel E, Feuerherd M, Tinnefeld K, Winter C, Ruland J, Gerhard M, Haller B, Christa C, Zelger O, Roggendorf H, Halle M, Erber J, Lingor P, Keppler O, Zehn D, Protzer U, Knolle PA
Nature communications 2022 Jan 10;13(1):153

Decreased Frequencies of Gamma/Delta T Cells Expressing Th1/Th17 Cytokine, Cytotoxic, and Immune Markers in Latent Tuberculosis-Diabetes/Pre-Diabetes Comorbidity.

Kathamuthu GR, Kumar NP, Moideen K, Menon PA, Babu S
Frontiers in cellular and infection microbiology 2021;11:756854

Characterization of humoral and SARS-CoV-2 specific T cell responses in people living with HIV.

Alrubayyi A, Gea-Mallorquí E, Touizer E, Hameiri-Bowen D, Kopycinski J, Charlton B, Fisher-Pearson N, Muir L, Rosa A, Roustan C, Earl C, Cherepanov P, Pellegrino P, Waters L, Burns F, Kinloch S, Dong T, Dorrell L, Rowland-Jones S, McCoy LE, Peppa D
Nature communications 2021 Oct 5;12(1):5839

Platelets stimulate programmed death-ligand 1 expression by cancer cells: Inhibition by anti-platelet drugs.

Asgari A, Lesyk G, Poitras E, Govindasamy N, Terry K, To R, Back V, Rudzinski JK, Lewis JD, Jurasz P
Journal of thrombosis and haemostasis : JTH 2021 Nov;19(11):2862-2872

NKD2 mediates stimulation-dependent ORAI1 trafficking to augment Ca(2+) entry in T cells.

Wu B, Woo JS, Vila P, Jew M, Leung J, Sun Z, Srikanth S, Gwack Y
Cell reports 2021 Aug 24;36(8):109603

A novel dual-cytokine-antibody fusion protein for the treatment of CD38-positive malignancies.

De Luca R, Kachel P, Kropivsek K, Snijder B, Manz MG, Neri D
Protein engineering, design & selection : PEDS 2018 May 1;31(5):173-179

Surrogate in vitro activation of innate immunity synergizes with interleukin-7 to unleash rapid antigen-driven outgrowth of CD4+ and CD8+ human peripheral blood T-cells naturally recognizing MUC1, HER2/neu and other tumor-associated antigens.

Pathangey LB, McCurry DB, Gendler SJ, Dominguez AL, Gorman JE, Pathangey G, Mihalik LA, Dang Y, Disis ML, Cohen PA
Oncotarget 2017 Feb 14;8(7):10785-10808

Anti-TNF drives regulatory T cell expansion by paradoxically promoting membrane TNF-TNF-RII binding in rheumatoid arthritis.

Nguyen DX, Ehrenstein MR
The Journal of experimental medicine 2016 Jun 27;213(7):1241-53

Transcriptional profile of tuberculosis antigen-specific T cells reveals novel multifunctional features.

Arlehamn CL, Seumois G, Gerasimova A, Huang C, Fu Z, Yue X, Sette A, Vijayanand P, Peters B
Journal of immunology (Baltimore, Md. : 1950) 2014 Sep 15;193(6):2931-40

Phenotypic and functional profiling of CD4 T cell compartment in distinct populations of healthy adults with different antigenic exposure.

Roetynck S, Olotu A, Simam J, Marsh K, Stockinger B, Urban B, Langhorne J
PloS one 2013;8(1):e55195

Differential expression of CD300a/c on human TH1 and TH17 cells.

Simhadri VR, Mariano JL, Zhou Q, DeBell KE, Borrego F
BMC immunology 2011 Nov 2;12:62

Human Th1 cells that express CD300a are polyfunctional and after stimulation up-regulate the T-box transcription factor eomesodermin.

Narayanan S, Silva R, Peruzzi G, Alvarez Y, Simhadri VR, Debell K, Coligan JE, Borrego F
PloS one 2010 May 13;5(5):e10636

Enhanced IL-10 production in response to hepatitis C virus proteins by peripheral blood mononuclear cells from human immunodeficiency virus-monoinfected individuals.

Barrett L, Gallant M, Howley C, Bowmer MI, Hirsch G, Peltekian K, Grant M
BMC immunology 2008 Jun 13;9:28

No comments: Submit comment

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Normal human peripheral blood cells were unstimulated (left) or stimulated with Cell Stimulation Cocktail (plus protein transport inhibitors) (Product # 00-4975-03) for 5 hours (right). The cells were intracellularly stained with Anti-Human CD4 APC (Product # 17-0047-42) and Rat IgG2a K Isotype Control FITC (Product # 11-4321-42) or Anti-Human IL-2 FITC. Viable cells, as determined by Fixable Viability Dye eFluor® 780 (Product # 65-0865-14), in the lymphocyte gate were used for analysis.
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: NULL
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1. NKD2 is involved in regulation of the Ca 2+ -NFAT signaling pathway in T cells (A) Representative immunoblot showing expression of NKD2 in lysates from HeLa cells, unstimulated Jurkat T cells, or those stimulated with PMA + ionomycin or anti-CD3 antibody (Ab) for 6 h. beta-Actin, loading control. Data are representative of two independent experiments. (B) Representative immunoblot showing expression of NKD2 in lysates of control or NKD2 knockout (KO) Jurkat T cells generated using two independent sgRNAs (#1 and #3). beta-Actin, loading control. Data are representative of two independent experiments. (C) Representative traces showing averaged SOCE from control (69 cells), NKD2 KO (KO sgRNA #1, 70 cells) Jurkat T cells, or NKD2 KO Jurkat T cells reconstituted for expression of NKD2 (KO sgRNA #1 + NKD2, 68 cells) after TCR stimulation using anti-CD3 antibodies, followed by ionomycin treatment in the presence of external solution containing 2 mM Ca 2+ . Bar graph (right) shows averaged baseline-subtracted SOCE (+-SEM) from three independent experiments with NKD2 KO cells generated using two independent sgRNAs (#1 and #3). (D) Representative immunoblot of NFATc2 levels in nuclear extracts from wild-type (WT) and NKD2 KO (sgRNA #1) Jurkat T cells stimulated with 1 muM ionomycin for indicated times. A nuclear protein, Ku86, was used as a loading control. Bar graph shows the densitometric analysis of relative band intensities of nuclear NFATc2. Data show means +- SEM of poo
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 6. NKD2-mediated ORAI1 + vesicle trafficking is crucial for the effector function of primary T cells (A) Representative histograms showing levels of NKD2 protein in primary T cells transduced with lentiviral vectors encoding scrambled sgRNA (control), NKD2 sgRNA #1, and NKD2 sgRNA #3, together with those encoding Cas9. Cells were permeabilized and stained with anti-NKD2 Ab. The bar graph (right) shows average (+-SEM) from four independent experiments. (B) Representative traces showing averaged SOCE from primary control (73 cells) and NKD2 KO (KO sgRNA #1, 82 cells; KO sgRNA #3, 71 cells) T cells after TCR stimulation using anti-CD3 Abs, followed by ionomycin treatment in the presence of external solution containing 2 mM Ca 2+ . Bar graph (right) shows averaged baseline-subtracted SOCE (+-SEM) from three independent experiments. (C) Representative histograms showing levels of newly inserted PM-resident ORAI1 protein in primary control and NKD2 KO effector T cells after TCR stimulation. Cells were transduced as described above to induce deletion of NKD2 and stimulated and stained as described in Figure 3B for detection of newly inserted PM-resident ORAI1. Bar graph (right) shows average (+-SEM) of pooled technical replicates from three independent donors. (D) Representative flow plots showing expression of IFN-gamma, IL-2, and TNF in control, NKD2 KO (sgRNA #1), and NKD2 KO (sgRNA #3) cells after re-stimulation with anti-CD3 and anti-CD28 Abs. Bar graph shows means +- SE
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 5 Rapid induction of polyfunctional IL-2-secreting T cells in convalescents and naive individuals after BNT162b2 mRNA vaccination. ( a ) frequencies of spike-reactive cytokine-secreting cells in convalescents (red, n = 50 (m11), n = 54 (vacc), n = 23 (boost)), and naive individuals (blue, n = 39 (m11), n = 49 (vacc), n = 40 (boost)) at month 11 after SARS-CoV-2 infection, two weeks after BNT162b2 mRNA prime vaccination (vacc) and 2 weeks after boost vaccination (boost). b Heatmap revealing frequencies of individuals bearing S1-reactive mono- or polyfunctional cytokine-secreting cells; convalescents (c), naive individuals (n). c Median and standard deviation for S1-reactive cytokine-secreting cells. d , e S1-reactive IL-2 and IFNgamma-producing CD4 and CD8 T cells in convalescents (red, n = 19) and naive individuals (blue, n = 31) determined directly ex vivo by flow cytometry using intracellular cytokine staining. Statistical analyses by ANOVA, two-sided Mann-Whitney and two-sided Wilcoxon signed-rank tests ( a , e ). n.s. denotes not significant; * p < 0.05; ** p < 0.01; **** p < 0.0001.
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: 5 FIGURE Platelets suppress T-cell activation by A549 cell an effect reversed by eptifibatide. (A) Representative flow cytometry dot plots and (B) summary data demonstrating IL-2 expression in Jurkat cells after 6 h of co-culture with A549 cells that were pre-treated with/without platelets and eptifibitide (10 muM). N = 7. *, p -value
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Fig. 4 Composition of SARS-CoV-2-specific T cells in convalescent HIV-negative and HIV-positive individuals. Intracellular cytokine staining (ICS) was performed to detect cytokine-producing T cells to the indicated peptide pools in HIV-negative (HIV-, n = 12) and HIV-positive individuals (HIV+, n = 11). a Representative flow cytometric plots for the identification of antigen-specific CD4 T cells based on double expression (CD154 + IFN-gamma + , CD154 + IL-2 + , and CD154 + TNF-alpha + ) following 6-h stimulation with media alone (control) or overlapping SARS-CoV-2 peptides against Spike pool 1 and 2 (Spike), Nucleoprotein (N), and Membrane protein (M) directly ex vivo. b Frequency of aggregated CD4 T-cell responses (CD154 + IFN-gamma + , CD154 + IL-2 + , and CD154 + TNF-alpha + ) against Spike, M/N or combined (Spike and M/N) peptide pools (HIV-, n = 12; HIV+, n = 11). Error bars represent SEM. c Pie charts representing the relative proportions of Spike, M/N, or total (combined Spike and M/N) CD4 T-cell responses for one (gray), two (green) or three (dark blue) cytokines, and pie arcs denoting IFN-gamma, TNF-alpha and IL-2. d Representative flow cytometric plots for the identification of antigen-specific CD8 T cells based on the expression of (IFN-gamma + , TNF-alpha + , and IL-2 + ) against the specified peptide pools or media alone (control). e Proportion of aggregated CD8 T-cell responses against Spike, M/N or combined (Spike and M/N) responses in HIV- ( n = 12) and HIV+ (
Conjugate: Green dye

Supportive validation

Submitted by: Invitrogen Antibodies (provider)
Main image
Experimental details: Figure 1 Decreased frequencies of gammadelta T cells expressing Th1 cytokines in LTB comorbidities. Peripheral blood mononuclear cells (PBMCs) were either untreated or treated with Mtb or positive control antigens for 18 h. The absolute (unstimulated, UNS) and antigen-stimulated (PPD, WCL, P/I) net frequencies of Th1 (IFNgamma, IL-2, TNFalpha) cytokines were shown in LTB DM (n = 20), LTB PDM (n = 20), and LTB NDM (n = 20) groups. Geometric mean values were represented using bars, and every circle denotes a single individual. Kruskal-Wallis test with multiple Dunn's comparison was used to determine the p values.
Conjugate: Green dye

11-7029-42

Antibody data